Celyad Oncology SA American Depositary Shares
CYAD
CYAD was delisted on the 18th of May, 2023.
6 hedge funds and large institutions have $6.8M invested in Celyad Oncology SA American Depositary Shares in 2016 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 2 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
14% less funds holding
Funds holding: 7 → 6 (-1)
37% less capital invested
Capital invested by funds: $10.9M → $6.8M (-$4.06M)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Victory Capital Management
San Antonio,
Texas
|
+$11K |
| 2 |
Morgan Stanley
New York
|
+$9.12K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$1.22K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$551 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$1.79M |
| 2 |
Zurich Cantonal Bank
Zurich,
Switzerland
|
-$140K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$2K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Victory Capital Management
San Antonio,
Texas
| $6.33M | +$11K | +580 | +0.2% |
|
|
DCM
2
DAFNA Capital Management
Los Angeles,
California
| $222K | – | – | – |
|
|
3
Zurich Cantonal Bank
Zurich,
Switzerland
| $187K | -$140K | -7,368 | -41% |
|
|
4
Morgan Stanley
New York
| $46K | +$9.12K | +480 | +23% |
|
|
TRCT
5
Tower Research Capital (TRC)
New York
| $7K | +$551 | +29 | +9% |
|
|
6
UBS Group
Zurich,
Switzerland
| $1K | +$1.22K | +64 | New |
|
|
CAM
7
Cormorant Asset Management
Boston,
Massachusetts
| – | -$1.79M | -75,920 | Closed |
|
|
8
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$2K | -70 | Closed |
|
CYAD Hedge Fund Activity: Q4 2016 in Review
6 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Celyad Oncology SA American Depositary Shares (CYAD) for Q4 2016, worth a combined $6.8M — down 37% from $10.9M a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of CYAD and 1 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 3 added.
The largest buyer was Victory Capital Management, adding an estimated $11K. The largest seller was Cormorant Asset Management, exiting entirely with an estimated $1.79M sold.
- 6 institutional investors held Celyad Oncology SA American Depositary Shares (CYAD) as of Q4 2016, down from 7 in Q3 2016.
- Funds reported $6.8M of Celyad Oncology SA American Depositary Shares stock for Q4 2016, down 37% quarter-over-quarter.
- 1 fund opened new Celyad Oncology SA American Depositary Shares positions in Q4 2016 and 2 closed out, a net change of -1 holder.
- The largest Celyad Oncology SA American Depositary Shares buyer in Q4 2016 was Victory Capital Management, an estimated $11K added.
- The largest Celyad Oncology SA American Depositary Shares seller in Q4 2016 was Cormorant Asset Management, an estimated $1.79M sold.
Based on aggregated 13F filings for Q4 2016.